Electrocortical changes associated with minocycline treatment in fragile X syndrome. - Wikidata - awgldk - TriplyDB

Electrocortical changes associated with minocycline treatment in fragile X syndrome.

Electrocortical changes associated with minocycline treatment in fragile X syndrome.

http://www.wikidata.org/entity/Q30378165

about

A delicate balance: role of MMP-9 in brain development and pathophysiology of neurodevelopmental disorders Emerging pharmacologic treatment options for fragile X syndrome Fragile X-associated tremor/ataxia syndrome.Reduced habituation of auditory evoked potentials indicate cortical hyper-excitability in Fragile X Syndrome Review of targeted treatments in fragile X syndrome Sensory processing in autism spectrum disorders and Fragile X syndrome-From the clinic to animal models.Matrix metalloproteinase-9 deletion rescues auditory evoked potential habituation deficit in a mouse model of Fragile X Syndrome Auditory processing in fragile x syndrome.Neural synchronization deficits linked to cortical hyper-excitability and auditory hypersensitivity in fragile X syndrome The Role of Proteases in Hippocampal Synaptic Plasticity: Putting Together Small Pieces of a Complex Puzzle.Updated report on tools to measure outcomes of clinical trials in fragile X syndrome.Fragile X targeted pharmacotherapy: lessons learned and future directions.Genetic removal of matrix metalloproteinase 9 rescues the symptoms of fragile X syndrome in a mouse model.Modulation of the GABAergic pathway for the treatment of fragile X syndrome.Resting-state EEG oscillatory dynamics in fragile X syndrome: abnormal functional connectivity and brain network organization Autism Spectrum Disorder (ASD) and Fragile X Syndrome (FXS): Two Overlapping Disorders Reviewed through Electroencephalography-What Can be Interpreted from the Available Information?Transient ECM protease activity promotes synaptic plasticity.The development of the N1 and N2 components in auditory oddball paradigms: a systematic review with narrative analysis and suggested normative values.Treatment of the psychiatric problems associated with fragile X syndrome.Pharmacotherapy for Fragile X Syndrome: Progress to Date.Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials.The Search for an Effective Therapy to Treat Fragile X Syndrome: Dream or Reality?Neural Hyperexcitability in Autism Spectrum Disorders.Developmental Emergence of Phenotypes in the Auditory Brainstem Nuclei of Fmr1 Knockout Mice.Auditory repetition suppression alterations in relation to cognitive functioning in fragile X syndrome: a combined EEG and machine learning approach.Potential Involvement of Impaired BKCa Channel Function in Sensory Defensiveness and Some Behavioral Disturbances Induced by Unfamiliar Environment in a Mouse Model of Fragile X Syndrome.The Perineuronal 'Safety' Net? Perineuronal Net Abnormalities in Neurological Disorders Fragile X syndrome Reusable Multielectrode Array Technique for Electroencephalography in Awake Freely Moving Mice Sensory Processing Phenotypes in Fragile X Syndrome

P2860

Q26797397-07F65E21-4A49-40A5-9747-B35A70B4A4C9 Q26829152-E5BE8B26-0B06-4055-BC93-2CB56C37449F Q26852667-42C679C7-BC6A-43B7-B20B-BC4DB6CB8647 Q27337789-51935B99-2E71-4B78-83B4-5BF74E8CDA6E Q28077180-C78C7280-A1F8-4D9F-95C2-6793F98F2A82 Q30354621-D8583607-B16A-4336-8A19-A458931EC557 Q30357779-677AFE4E-B431-4596-9AE7-F7B3B81D565D Q30442883-0EA766E7-93A5-4533-9192-5124DD34BE70 Q30855165-7180598E-0AF5-4D4B-B272-292974B2B284 Q33361879-3FA8F2DF-9F1B-4878-9D0F-FEEF4CDB21B4 Q33785978-D271931D-5174-4268-8661-12A58F88C982 Q33785983-3D21AA2E-9D30-46E5-8C48-A94144182162 Q33935973-E7662578-3694-4644-A703-53E107AA9BFF Q34230612-BAFC81DD-624C-4D54-8BC9-FED5FB7879A1 Q35093626-CCED764E-A193-4F6E-9A82-77D353C24EFD Q35824354-F8F82A5A-31AA-4E12-AEFA-1C05E68F7270 Q36990679-F7AD2A9A-2ADC-4FB0-A52E-C499FCA1C9E0 Q38222892-546B021E-7DDC-4F3B-AB8D-63C0FF667CD5 Q38324675-9A3AEE80-E222-486E-B909-DCCB2C1C5D32 Q38726962-D9A8A694-16AD-494A-839C-487B463C5AA0 Q38921198-2A8BE495-BD33-440F-89B9-66BBEFDB42EA Q47110293-0DD04447-ED20-41EE-96BF-8F33AE53A834 Q47136579-77BB082C-39EC-4380-96AC-30768EDC71F2 Q47164654-621D1F03-612A-4FEA-9CBC-3915DF8F9B98 Q47834032-D1713524-4927-49D9-B196-D3E8D3ADA4CD Q48104405-182CA019-C8F7-4689-8B4D-6F24C0D3FBA6 Q57170923-A3D92316-22B1-496E-BF12-8F16A61287EC Q57828399-79B1EA23-D0EB-4C7D-ADC8-6A5CFC67344E Q58707302-362395E5-3FD7-4DD6-A162-1F3CFDC1F04E Q58718525-37C10F4B-2B6D-4810-8360-CFC0FCC401E7

P2860

Electrocortical changes associated with minocycline treatment in fragile X syndrome.

http://www.wikidata.org/entity/Q30378165

description

2013 nî lūn-bûn

@nan

2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Electrocortical changes associated with minocycline treatment in fragile X syndrome.

@ast

Electrocortical changes associated with minocycline treatment in fragile X syndrome.

@en

type

label

Electrocortical changes associated with minocycline treatment in fragile X syndrome.

@ast

Electrocortical changes associated with minocycline treatment in fragile X syndrome.

@en

prefLabel

Electrocortical changes associated with minocycline treatment in fragile X syndrome.

@ast

Electrocortical changes associated with minocycline treatment in fragile X syndrome.

@en

P1433

Q30378165-46E11C8A-3504-4FC6-9837-C351F938D77D

P1476

Q30378165-BDA23D5A-C0AF-44A6-AE88-026545E56C80

P2093

Q30378165-2031AC0C-3D04-49CA-923F-322ADB3C9ED0

Q30378165-34F6B4EF-B49E-4952-A7C8-203D012DCE8E

Q30378165-808889AD-F25B-4D35-B7DD-11B95BDADF0C

Q30378165-9A415DFE-9412-4FA8-8EBF-0293B00E443E

Q30378165-B462090E-B1C9-4B0D-BDBD-769D78D10FD6

Q30378165-BD875678-65D2-48B0-8991-84F3BB203BF6

Q30378165-E2483C54-AB81-4BBC-A72F-C9540F80C950

Q30378165-F343B820-4C58-4688-8C41-ED8B587A70F1

P2860

Q30378165-05AFC1E1-2555-46DB-B61D-CB096F9814E5

Q30378165-1ADD6EA7-B51E-4AA4-8DEE-98E4B430FF12

Q30378165-232BB278-1ED9-4896-93EC-38C01BC805B0

Q30378165-27A2D5C6-8AE8-498D-8BAE-ED8244B62DA2

Q30378165-311CD20B-0FAD-4954-AB29-FFBDF5589B86

Q30378165-347259E8-DD97-4D8E-9676-FC3F49B31440

Q30378165-35BB93D6-DE5F-462D-A1C0-20D3948FE814

Q30378165-41BF287C-63F4-4752-BEE7-21D74B8F30EC

Q30378165-44CCC15D-D22D-424E-AFA9-57A4E94BF9ED

Q30378165-47F34878-106E-465C-810F-EBB988F8A0FC

P304

Q30378165-1BF2295F-2C38-44C4-AE53-D0CD4AEE089E

P31

Q30378165-7E412BFE-075C-46E4-A365-D0DCF50E6061

P356

Q30378165-29B6AD6C-E65A-4248-A799-38ACDE37AA15

P407

Q30378165-65847D7C-CB6B-4C7E-BBD7-C57FC8EF510A

P433

Q30378165-7EF264C2-5B21-4E6D-9DB2-84C4F4EBF44B

P478

Q30378165-228BAEEC-307E-4A42-86AD-2D834E76D12F

P577

Q30378165-A2D813F0-2199-4E59-B2CF-C8D5A56CDDC8

P698

Q30378165-2D55065A-E4A0-4A0A-8EDB-C05515E4A9A0

P932

Q30378165-5E9D4D23-3D77-4BD4-8492-EF87B3E3C7D6

P356

0269881113494105

P1433

Journal of Psychopharmacology

P1476

Electrocortical changes associated with minocycline treatment in fragile X syndrome.

@en

P2093

Andrea Schneider

http://www.w3.org/2001/XMLSchema#string

David Hessl

http://www.w3.org/2001/XMLSchema#string

John Olichney

http://www.w3.org/2001/XMLSchema#string

Mary Jacena Leigh

http://www.w3.org/2001/XMLSchema#string

Patrick Adams

http://www.w3.org/2001/XMLSchema#string

Randi Hagerman

http://www.w3.org/2001/XMLSchema#string

Rawi Nanakul

http://www.w3.org/2001/XMLSchema#string

Tasleem Chechi

http://www.w3.org/2001/XMLSchema#string

P2860

The mGluR theory of fragile X mental retardation

Prepulse inhibition in fragile X syndrome: feasibility, reliability, and implications for treatment.

BC1 regulation of metabotropic glutamate receptor-mediated neuronal excitability.

Abnormal dendritic spine characteristics in the temporal and visual cortices of patients with fragile-X syndrome: a quantitative examination.

Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures

Open-label add-on treatment trial of minocycline in fragile X syndrome.

Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056.

Generator localization by current source density (CSD): implications of volume conduction and field closure at intracranial and scalp resolutions.

The GABAA receptor: a novel target for treatment of fragile X?

Event-related potentials in clinical research: guidelines for eliciting, recording, and quantifying mismatch negativity, P300, and N400.

P304

956-963

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0269881113494105

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23981511

http://www.w3.org/2001/XMLSchema#string

P932

4962861

http://www.w3.org/2001/XMLSchema#string